Innovative Therapeutics in Oncology and Neuroscience

2 Path to Profitability Through Top-Line Growth and Operational Efficiencies 11 Revenues COGS SG&A R&D Strong revenue growth Target 50% CAGR for 2023-2028 • New product launches and maximize potential with new indications Significant room for improvement Increase in scale • Potential for more local manufacturing Increased productivity with synergies • Leveraging existing infrastructure to support new launches • Cost initiatives in place Capital efficient spending Continued portfolio prioritization Abbreviations: compound annual growth rate (CAGR), cost of goods sold (COGS), research and development expenses (R&D), selling, general and administrative expenses (SG&A). zaiLab

View entire presentation